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Background
Pembrolizumab is an antibody designed against pro-
grammed cell-death protein-1 (PD-1), which is
expressed on the surface of activated T cells. Tumor
cells can upregulate PD-L1, which binds to PD-1 and
mediates T cell anergy. By antagonizing the PD-1/PD-
L1 binding, pembrolizumab can enhance T cell killing
in multiple tumor types. RT can be immunostimulatory,
therefore, combination therapy may yield enhanced effi-
cacy. Here, we evaluated the immune biomarkers related
to a patient who failed combined treatment with radia-
tion and pembrolizumab.
Methods
Phase I clinical trial (NCT02318771) designed to investi-
gate the immunomodulatory effects of radiation therapy
in combination with pembrolizumab. The study rando-
mizes patients to one of four arms: fractionated versus
single fraction radiation and pembrolizumab before or
after RT. The study enrolls patients with metastatic
lung, renal, head and neck cancers, and melanoma.
Peripheral blood was obtained before, during, and after
treatment were analyzed using flow cytometry. CT
guided biopsies of the tumor before and after radiation
treatment was preformed and the biopsy samples were
subject to RT-PCR analysis.
Results
The patient was randomized to fractionated radiation
20 Gy in 5 fractions to an anterior chest wall metastasis.
Following RT he received 5 cycles of pembrolizumab.
He was found to have disease progression at radiated
chest wall lesion as well as non-radiated metastatic sites
on subsequent image studies. Flow cytometry analysis of
his peripheral lymphocyte substance revealed no change
in CD8+ cells from baseline (25%) compared to post-
radiation (24%) and post-pembrolizumab (24%). CD4+
cells at baseline, post-RT and post-pembrolizumab were
43%, 42% and 35%. Flow cytometry of peripheral blood
post-pembrolizumab revealed high level of PD-1 expres-
sion on CD8 cells, with low level expression of PD-1 on
CD4 cells. RT-PCR on biopsies taken pre-RT and post-
RT revealed no T lymphocyte transcripts.
Conclusions
We present a patient with metastatic clear cell RCC who
experienced rapid disease progression following combi-
nation treatment. The patient failed to demonstrate
expansion of CD8 lymphocytes, the CD4 cells failed to
express PD-1 marker and the tumor biopsy before and
after RT failed to demonstrate the presence of T lym-
phocytes. We hypothesize that the lack of tumor infil-
trating lymphocytes may play a role in treatment failure.
Alternatively, we hypothesize that the tumor microenvir-
onment is heterogeneous with known non-redundant
immune checkpoints, which may have contributed to
treatment failure. Currently, we are exploring alternative
mechanisms of resistance to pembrolizumab by analyz-
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